关于上海艾力斯医药科技股份有限公司 非经营性资金占用及其他关联资金往来情况 的专项说明 非经营性资金占用及其他关联资金往来情况的专项说明 安永华明（2025）专字第80013571_B02号 上海艾力斯医药科技股份有限公司 上海艾力斯医药科技股份有限公司董事会： 我们审计了上海艾力斯医药科技股份有限公司的2024年度财务报表，包括2024年 12月31日的合并及公司资产负债表，2024年度的合并及公司利润表、股东权益变动表 和现金流量表以及相关财务报表附注，并于2025年4月22日出具了编号为安永华明 （2025）审字第80013571_B01号的无保留意见审计报告。 按照《上市公司监管指引第8号——上市公司资金往来、对外担保的监管要求》的 要求，上海艾力斯医药科技股份有限公司编制了后附的2024年度非经营性资金占用及 其他关联资金往来情况汇总表（以下简称"汇总表"）。 如实编制和对外披露汇总表，并确保其真实性、合法性、完整性是上海艾力斯医 药科技股份有限公司的责任。我们对汇总表所载资料与我们审计上海艾力斯医药科技 股份有限公司2024年度财务报表时所复核的会计资料和经审计的财务报表的相关内容 进行了核对，在 ...

上海艾力斯医药科技股份有限公司 内部控制审计报告 2024年12月31日 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制评价 指引》的规定，建立健全和有效实施内部控制，并评价其有效性是企业董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发表审计 意见，并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外，由于情况 的变化可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低，根据内 部控制审计结果推测未来内部控制的有效性具有一定风险。 内部控制审计报告 安永华明（2025）专字第80013571_B01号 上海艾力斯医药科技股份有限公司 上海艾力斯医药科技股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我们审 计了上海艾力斯医药科技股份有限公司2024年12月31日的财务报告内部控制的有效性。 一、企业对内部控制的责任 （本页无正文） 安永华明会计师事务所（特殊普通合伙） 中国注册会计师：吴慧珺 中国注册 ...

上海艾力斯医药科技股份有限公司 2024 年度募集资金存放与使用情况的专项核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为上海艾 力斯医药科技股份有限公司（以下简称"艾力斯"或"公司"）首次公开发行的 持续督导保荐人，根据《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》《上海证 券交易所科创板上市公司自律监管指引第 1 号——规范运作》等有关规定，对公 司 2024 年度募集资金的存放和使用情况进行了专项核查，核查情况如下： 一、募集资金基本情况 （一）实际募集资金的金额及到账情况 中信证券股份有限公司关于 根据中国证券监督管理委员会于 2020 年 10 月 12 日签发的证监许可 [2020]2559 号文《关于同意上海艾力斯医药科技股份有限公司首次公开发行股票 注册的批复》，公司在境内首次公开发行 90,000,000 股人民币普通股 A 股股票， 每股发行价格为人民币 22.73 元，股款以人民币缴足，计人民币 2,045,700,000.00 元，扣除承销及保荐费用、律师费、审计验资费、信息披露费以及其他发 ...

一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 3.1800 | 1.4300 | 122.38 | 0.2900 | | 每股净资产（元） | 11.74 | 8.85 | 32.66 | 7.08 | | 每股公积金(元) | 7.23 | 7.05 | 2.55 | 6.89 | | 每股未分配利润(元) | 2.77 | 0.51 | 443.14 | -0.84 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 35.58 | 20.18 | 76.31 | 7.91 | | 净利润(亿元) | 14.3 | 6.44 | 122.05 | 1.31 | | 净资产收益率(%) | 29.26 | 17.97 | 62.83 | 4.24 | 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 27506.31万股，累计占流通股比： 61 ...

最新一期业绩显示，2024年三季报，公司实现营业收入25.33亿元，同比87.97%；净利润10.63亿元，同 比158.99%，销售毛利率95.80%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)89艾力斯28.4928.498.34405.68亿行业平均 47.6146.435.52121.83亿行业中值28.5729.482.2351.14亿1赛托生物-4481.3182.361.9337.56亿2泽璟制 药-224.99-206.6523.23284.83亿3亚太药业-146.92-205.304.9124.38亿4共同药业-130.0778.822.1518.13亿 5*ST景峰-91.55-18.93-37.5044.69亿6江苏吴中-83.61-43.951.7631.62亿7翰宇药业-69.42-69.4217.72125.24 亿8微芯生物-59.65-59.654.5068.35亿9一品红-50.9694.938.03175.26亿10拓新药业-47.3014.162.1934.42亿 11易瑞生物-43.98-19.474.5936.00亿 本文源自：金融界 作者：行情君 4 ...

Group 1 - The core viewpoint of the articles highlights the performance and market position of Ailis, a company focused on innovative cancer treatment drugs, particularly in the non-small cell lung cancer sector [1][2] - As of April 15, Ailis closed at 86.63 yuan, down 1.33%, with a rolling price-to-earnings (PE) ratio of 27.37 times, and a total market capitalization of 38.983 billion yuan [1] - The average PE ratio for the chemical pharmaceutical industry is 45.73 times, with a median of 25.62 times, placing Ailis at the 95th position in the industry ranking [1][2] Group 2 - As of the third quarter of 2024, 367 institutions hold shares in Ailis, with a total of 40.9648 million shares valued at 2.454 billion yuan [1] - Ailis has developed a rich pipeline in the field of small molecule targeted drugs for non-small cell lung cancer, with its main products including Aifuratinib (a third-generation EGFR-TKI) and Alisartan [1] - The latest financial results show that for the third quarter of 2024, Ailis achieved a revenue of 2.533 billion yuan, a year-on-year increase of 87.97%, and a net profit of 1.063 billion yuan, a year-on-year increase of 158.99%, with a gross profit margin of 95.80% [1]

Company Overview - Shanghai Ailis Pharmaceutical Technology Co., Ltd. focuses on innovative drugs for cancer treatment, with key products including Aifuritini (third-generation EGFR-TKI) and Alisartan [1] - The company has developed a rich R&D pipeline in the field of small molecule targeted drugs for non-small cell lung cancer [1] - Ailis has successfully developed and transferred its independently researched product, Alisartan tablets, which is part of a major national project for new drug creation [1] Financial Performance - As of the latest Q3 2024 report, the company achieved a revenue of 2.533 billion yuan, representing a year-on-year increase of 87.97% [1] - The net profit for the same period was 1.063 billion yuan, showing a significant year-on-year growth of 158.99% [1] - The sales gross margin stood at 95.80% [1] Market Position - Ailis's current closing price is 85.63 yuan, with a PE ratio of 27.06, which is lower than the industry average of 47.09 [2] - The total market capitalization of the company is 38.533 billion yuan [2] - Among 147 institutions holding Ailis shares, the total number of shares held is 24.0823 million, with a market value of 1.443 billion yuan [1]

Group 1 - The core viewpoint is that the healthcare ETF Taikang (159760) has seen a 1.75% increase, driven by a recovering macroeconomic environment, which is expected to boost the growth rate of healthcare service revenues [1] - The Taikang healthcare ETF closely tracks the National Index of Public Health and Healthcare, which reflects the market performance of publicly listed companies in the public health and healthcare sector in the A-share market [1] - The top ten weighted stocks in the National Index of Public Health and Healthcare as of February 28, 2025, include Mindray Medical, Hengrui Medicine, WuXi AppTec, and others, accounting for a total of 52.4% of the index [1] Group 2 - Guotai Junan Securities indicates that in 2024, external consumption and medical insurance environments are under pressure, leading to a decline in the unit price of specialized medical services such as ophthalmology and dentistry, resulting in slowed growth [2] - Despite the slowdown in revenue growth, the demand for medical services remains strong, and as the macro economy gradually recovers, residents' payment capabilities and consumer confidence are expected to improve, leading to a rebound in revenue growth [2] - The rapid development of AI technology is expected to bring significant changes to the healthcare industry, with the healthcare ETF Taikang (159760) likely to continue benefiting from this trend [2]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology sector [2] Core Insights - The pharmaceutical sector continues to show strong performance, with a year-to-date return of +4.0%, outperforming the Shanghai Composite Index by 2.2% [4][11] - The report highlights the potential for recovery in consumer healthcare, driven by recent government policies aimed at boosting consumption [4][11] - Key investment themes include innovation in pharmaceuticals, turnaround opportunities, and the integration of AI technologies [4][11] Summary by Sections Market Performance - The Shanghai Composite Index rose by 1.59%, while the pharmaceutical sector increased by 1.77%, ranking 15th among 31 sub-industries [4][11] - Specific segments such as pharmaceutical commerce, traditional Chinese medicine, and medical services saw increases of 6.44%, 2.63%, and 1.46% respectively [4][11] Key Companies and Recommendations - Recommended stocks include WuXi AppTec, Aier Eye Hospital, Dong-E E-Jiao, and others, with expected earnings growth and favorable valuations [2][8] - The report emphasizes the importance of focusing on companies with improving fundamentals and low valuations, particularly in the eye care and dental sectors [5][11] Policy and Regulatory Developments - Recent government initiatives, including the introduction of child-rearing subsidies, are expected to positively impact the reproductive and maternal health sectors [6][7] - The National Healthcare Security Administration's guidelines for brain-computer interface services are anticipated to accelerate commercialization in this emerging field [6][11] Valuation Metrics - The pharmaceutical sector is currently valued at 23.4 times PE based on 2025 earnings forecasts, representing a 36.0% premium over the broader A-share market [17] - The TTM valuation stands at 27.3 times PE, which is below the historical average of 35.1 times PE, indicating potential for valuation recovery [17]

Investment Rating - The report initiates coverage with a "Buy" rating for the company [3][30]. Core Insights - The company focuses on lung cancer treatment, with its core product, Furmetinib, experiencing rapid growth. It targets rare EGFR mutations and expands into overseas markets. The pipeline is rich, and the company continues to enhance its presence in the lung cancer sector [3][19]. - The projected earnings per share (EPS) for 2024, 2025, and 2026 are estimated at 3.17, 3.87, and 4.72 yuan, respectively. The target price is set at 104.74 yuan based on absolute and relative valuation methods [3][30]. Financial Summary - Revenue is expected to grow from 791 million yuan in 2022 to 5,618 million yuan in 2026, reflecting a compound annual growth rate (CAGR) of 49.2% to 21.9% [5]. - Net profit attributable to the parent company is projected to increase from 131 million yuan in 2022 to 2,125 million yuan in 2026, with a significant growth rate of 614.2% in 2023 [5]. - The company’s price-to-earnings (P/E) ratio is expected to decrease from 268.92 in 2022 to 16.52 in 2026, indicating improving profitability [5]. Product and Market Positioning - Furmetinib is positioned as a potential best-in-class EGFR-TKI, with significant advantages in efficacy and safety, particularly for patients with brain metastases. The product has shown rapid market uptake since its launch [3][19]. - The company is expanding its focus on rare EGFR mutations, with ongoing clinical trials for Exon20ins and PACC mutations, aiming for global market penetration [3][19]. Pipeline Development - The company has a diverse pipeline, including partnerships for the development of RET inhibitors and KRAS inhibitors, which are expected to enhance its competitive positioning in the lung cancer treatment market [3][19][38]. - The collaboration with ArriVent for global expansion of Furmetinib's indications is a strategic move to capture a larger market share [3][19].